Opus Genetics Inc
NASDAQ:IRD

Watchlist Manager
Opus Genetics Inc Logo
Opus Genetics Inc
NASDAQ:IRD
Watchlist
Price: 2.13 USD -9.75% Market Closed
Market Cap: 146.9m USD

Net Margin
Opus Genetics Inc

-466.1%
Current
-164%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-466.1%
=
Net Income
-68.2m
/
Revenue
14.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Opus Genetics Inc
NASDAQ:IRD
137.5m USD
-466%
US
Eli Lilly and Co
NYSE:LLY
993.4B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
508.5B USD
27%
CH
Roche Holding AG
SIX:ROG
256.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
16%
CH
Novartis AG
SIX:NOVN
206.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
243.7B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.5B USD
16%
No Stocks Found

Opus Genetics Inc
Glance View

Market Cap
137.5m USD
Industry
Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 14 full-time employees. The company went IPO on 2004-11-30. The firm is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

IRD Intrinsic Value
0.63 USD
Overvaluation 70%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-466.1%
=
Net Income
-68.2m
/
Revenue
14.6m
What is the Net Margin of Opus Genetics Inc?

Based on Opus Genetics Inc's most recent financial statements, the company has Net Margin of -466.1%.

Back to Top